Oncotherapy Science, Inc.
Records under this name other than the patents Oncotherapy Science, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 68 patents it holds.
Back to Oncotherapy Science, Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,091,517 | Peptide Derivative and Pharmaceutical Composition Containing Same now held by Tokushima University In force · High confidence | In force | High confidence | |
| US 11,598,780 | Engineering Lymphocytes with Specific Alpha and Beta Chains on Their T-Cell Receptor now held by The University of Chicago In force · High confidence | In force | High confidence | |
| US 12,595,289 | Therapeutic Agent for Breast Cancer Comprising BIG3-PHB2 Interaction-Inhibiting Peptide Derived from PHB2 now held by Tokushima University In force · High confidence | In force | High confidence | |
| US 12,780,880 | SARS-CoV-2 PROTEIN-DERIVED PEPTIDE AND VACCINE CONTAINING SAME now held by Cancer Precision Medicine, Inc. In force · High confidence | In force | High confidence | |
| US 7,919,099 | Epitope Peptides Derived from Vascular Endothelial Growth Factor Receptor 1 and Vaccines Containing These Peptides Term ended Term ended Sep 25, 2026 · High confidence | Term ended | Term ended Sep 25, 2026 | High confidence |
| US 8,709,731 | DKK1 Oncogene as Therapeutic Target for Cancer and a Diagnosing Marker Lapsed on the fee record Ended Apr 29, 2026 · High confidence | Lapsed on the fee record | Ended Apr 29, 2026 | High confidence |
| US 7,847,060 | Peptide Vaccines for Lung Cancers Expressing TTK, URLC10 or KOC1 Polypeptides Term ended Term ended Feb 17, 2026 · High confidence | Term ended | Term ended Feb 17, 2026 | High confidence |
| US 8,586,547 | CDC45L Peptides and Vaccines Including the Same Lapsed on the fee record Ended Nov 19, 2025 · High confidence | Lapsed on the fee record | Ended Nov 19, 2025 | High confidence |
| US 8,697,068 | Method for Treating Synovial Sarcoma Term ended Term ended Sep 1, 2025 · High confidence | Term ended | Term ended Sep 1, 2025 | High confidence |
| US 7,803,370 | Method for Treating Synovial Sarcoma Term ended Term ended Apr 20, 2025 · High confidence | Term ended | Term ended Apr 20, 2025 | High confidence |